Dalton WS - Search Results

1

Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Dalton WS, et al. Hematology Am Soc Hematol Educ Program. 2001:157-77. doi: 10.1182/asheducation-2001.1.157. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722983 Review.

2

Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma.

Bensinger WI, Buckner CD, Clift RA, Petersen FB, Bianco JA, Singer JW, Appelbaum FR, Dalton W, Beatty P, Fefer A, et al. Bensinger WI, et al. J Clin Oncol. 1992 Sep;10(9):1492-7. doi: 10.1200/JCO.1992.10.9.1492. J Clin Oncol. 1992. PMID: 1517792 Clinical Trial.

3

Drug resistance in myeloma: mechanisms and approaches to circumvention.

Dalton WS, Salmon SE. Dalton WS, et al. Hematol Oncol Clin North Am. 1992 Apr;6(2):383-93. Hematol Oncol Clin North Am. 1992. PMID: 1582980 Review.

4

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.

Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. Dalton WS, et al. Cancer. 1995 Feb 1;75(3):815-20. doi: 10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r. Cancer. 1995. PMID: 7828131 Clinical Trial.

5

Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid.

Glasser L, Dalton WS, Fiederlein RL, Cook P, Powis G, Vogler WR. Glasser L, et al. Among authors: dalton ws. Exp Hematol. 1996 Feb;24(2):253-7. Exp Hematol. 1996. PMID: 8641349

6

Detection of multidrug resistance gene expression in multiple myeloma.

Dalton WS. Dalton WS. Leukemia. 1997 Jul;11(7):1166-9. doi: 10.1038/sj.leu.2400724. Leukemia. 1997. PMID: 9205007 Review.

7

Mutations in the Fas antigen in patients with multiple myeloma.

Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Landowski TH, et al. Among authors: dalton ws. Blood. 1997 Dec 1;90(11):4266-70. Blood. 1997. PMID: 9373236 Free article.

8

Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model.

Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Turner JG, et al. Among authors: dalton ws. Hum Gene Ther. 1998 May 20;9(8):1121-30. doi: 10.1089/hum.1998.9.8-1121. Hum Gene Ther. 1998. PMID: 9625251

9

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Catlett-Falcone R, et al. Among authors: dalton ws. Immunity. 1999 Jan;10(1):105-15. doi: 10.1016/s1074-7613(00)80011-4. Immunity. 1999. PMID: 10023775 Free article.

10

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Damiano JS, et al. Among authors: dalton ws. Blood. 1999 Mar 1;93(5):1658-67. Blood. 1999. PMID: 10029595 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters